Acceptance Of Regulatory Submissions By U.S. FDA And European Medicines Agency By Pfizer

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery.In addition, the European Medicines Agency (EMA) has validated for review a Type II Variation application for SUTENT in the same patient population. SUTENT is the most widely prescribed first-line treatment for advanced RCC worldwide.

More:
www.businesswire.com/news/home/20170531005542/en/Pfizer-Announces-Acceptance-Regulatory-Submissions-U.S.-FDA